82.7 F
New York
Friday, July 30, 2021

Relay Therapeutics [NASDAQ: RLAY] Signs A Collaborative Contract With Genetech For Development Of RLY-1971

Must read

Ucommune [NASDAQ: UK] Ink Cooperation Agreement with Beijing Investment Group

Ucommune International Ltd. inked a cooperation agreement with Beijing Investment Group Co., LTD. Beijing Investment is a fully state-owned land developer associated with...

Lion Electric [NYSE: LEV] all Set to Deliver Two Electric Trucks to Green Mountain Power

The Lion Electric Company revealed on Friday that it is preparing to deliver two of its all-electric trucks to Green Mountain Power (GMP)...

Digital Realty [NYSE: DLR] Considering Developing 64 MW Facility in South Korea

Digital Realty Trust, Inc. has shown its intention to build the 64-megawatt facility in Seoul, South Korea. The firm has decided that the...

Why Shares of IZEA Worldwide [NASDAQ: IZEA] Skyrocketing Today?

Shares of IZEA Worldwide, Inc. surged 8.10% at the time of writing on Wednesday. The strong performance of the firm has highlighted the...

Relay Therapeutics [NASDAQ: RLAY] revealed that the company inked a contract with Genetech. Both the companies agreed on the development and commercialization of RLY-1971. The drug is a strong inhibitor of SHP2. The drug is a possible pillar to serve in combination therapy to treat various tumors.

Genetech will take charge of the development of RLY-1971 with the possibility of expanding the drug into multiple combination studies. According to the terms of the worldwide license and collaboration agreement, Relay will receive a $75 million payment. The company is further eligible to receive $25M in additional payment. Relay has an option of a 50/50 profit/cost-share on the drug. The company will be eligible to receive a 50% profit from U.S sales. It will also receive $410M in additional payment and royalties on net sales if it opts for it.

If Relay chooses otherwise, the company will be eligible to obtain $695M in additional development, commercialization, and royalties on net sales. Relay still holds the right to combine with it’s FGFR2 and PI3Kα programs.

More articles

Latest article

BIT Mining [NYSE: BTCM] Ink Purchase Agreement to Buy Bitcoin Mining Machine

BIT Mining Limited has inked a purchase agreement to increase the fleet of bitcoin mining machines. As per the new purchase agreement, the...

Dyadic International [NASDAQ: DYAI] Inks Licensing Agreement with the Rubic Consortium

Dyadic International, Inc. disclosed that it has inked a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium. It has been...

Binance, FTX Cut Leverage Limits on Crypto Futures Trading to 20x

Two major cryptocurrency trading platforms Binance Futures and FTX disclosed on Monday that they both have made a remarkable decision related to the crypto...

TD Holdings [NASDAQ: GLG] Inks Letter of Intent with Guangdong Jinbochuang

TD Holdings, Inc. has inked a letter of intent (LOI) with Guangdong Jinbochuang Special Purpose Vehicle Co., Ltd. and (Jinbochuang) and Hunan Jinmeike...

ASGN [NYSE: ASGN] Acquire IndraSoft Inc

ASGN Incorporated disclosed that it has acquired IndraSoft Inc. IndraSoft Inc has gained recognition as a prominent cybersecurity and digital transformation solutions offeror...

Link Reservations Decides to Accept Bitcoin/Crypto Payments

Link Reservations Inc disclosed Friday that it has decided to start accepting Bitcoin and cryptocurrency payments. This is the major breakthrough for the firm...

Athene [NYSE: ATH] Announces Acquisition of Foundation Home Loans

Athene Holding Ltd. disclosed on Thursday that it has inked a definitive agreement to purchase Foundation Home Loans (FHL). FHL had a £3...

Ping [NYSE: PING] and Anexinet Announces Partnership

Ping Identity Holding Corp. and Anexinet Corporation have both entered into a partnership agreement. The collaboration will integrate Ping Identity’s centralized Identity Access...